ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.99
−2.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 67.4M | — | — |
| Cost of Revenue | 151.0K | — | — | — | — |
| Gross Profit | (151.0K) | — | 67.4M | — | — |
| Operating Expenses | |||||
| R&D Expense | 145.0M | 107.3M | 167.8M | 235.2M | 172.7M |
| SG&A Expense | 46.0M | 37.7M | 87.1M | 59.4M | 54.6M |
| General & Admin Expense | 46.2M | 37.7M | 87.1M | 59.4M | 54.6M |
| Selling & Marketing Expense | (151.0K) | — | — | — | — |
| Other Expenses | — | 7.8M | 3.7M | 5.0M | — |
| Total Operating Expenses | 191.1M | 152.8M | 258.6M | 299.5M | 227.3M |
| Cost and Expenses | 191.2M | 152.8M | 258.6M | 299.5M | 227.3M |
| Operating Income (EBIT) | (191.2M) | (152.8M) | (191.2M) | (299.5M) | (227.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 2.3K |
| Interest Expense | — | — | — | — | 2.6M |
| Net Interest Income | — | — | — | — | (2.6M) |
| Other Non-Op Income/Expense | 17.2M | 16.2M | 25.5M | 6.6M | (10.3M) |
| Non-Operating Income (excl Interest) | (17.2M) | (7.8M) | (3.7M) | (50.5M) | 7.7M |
| EBT (Pre-Tax Income) | (174.1M) | (136.6M) | (165.7M) | (292.9M) | (237.6M) |
| Income Tax Expense | 820.0K | 442.0K | 177.0K | (601.0K) | (469.0K) |
| Bottom Line | |||||
| Net Income | (174.9M) | (137.1M) | (165.8M) | (292.2M) | (236.8M) |
| Earnings from Cont. Ops | (174.9M) | (137.1M) | (165.9M) | (292.3M) | (237.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (174.9M) | (137.1M) | (165.8M) | (292.2M) | (236.8M) |
| Per Share | |||||
| Basic EPS | ($2.46) | ($1.91) | ($2.33) | ($4.47) | ($4.48) |
| Diluted EPS | ($2.46) | ($1.91) | ($2.33) | ($4.47) | ($4.48) |
| Revenue Per Share | $0.00 | $0.00 | $0.95 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 70.3M | 71.9M | 71.1M | 65.4M | 52.9M |
| Diluted Shares Outstanding | 70.3M | 71.9M | 71.1M | 65.4M | 52.9M |
| Profitability Metrics | |||||
| EBITDA | (173.5M) | (144.3M) | (186.2M) | (247.6M) | (233.6M) |
| D&A | 621.0K | 739.0K | 1.3M | 1.4M | 1.4M |
| EBIT | (174.1M) | (145.0M) | (187.5M) | (249.0M) | (235.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026